Intra-Cellular Therapies, Inc. (ITCI)

NASDAQ: ITCI · IEX Real-Time Price · USD
68.20
-1.52 (-2.18%)
Mar 28, 2024, 12:48 PM EDT - Market open

Company Description

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.

The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications.

In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders.

Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies logo
Country United States
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 610
CEO Dr. Sharon Mates Ph.D.

Contact Details

Address:
430 East 29th Street
New York, New York 10016
United States
Phone 212-923-3344
Website intracellulartherapies.com

Stock Details

Ticker Symbol ITCI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001567514
CUSIP Number 46116X101
ISIN Number US46116X1019
Employer ID 36-4742850
SIC Code 2834

Key Executives

Name Position
Dr. Sharon Mates Ph.D. Co-Founder, Chairman and Chief Executive Officer
Michael I. Halstead J.D. President
Dr. Suresh K. Durgam M.D. Executive Vice President and Chief Medical Officer
Mark Neumann Executive Vice President and Chief Commercial Officer
Dr. Robert E. Davis Ph.D. Senior Vice President and Chief Scientific Officer
Juan Fernando Sanchez Vice President of Corporate Communications and Investor Relations
Karen Patruno Sheehy Esq. Senior Vice President and Chief Compliance Officer
Dr. Michael Olchaskey Senior Vice President and Head of Regulatory Affairs
John A. Bardi Senior Vice President of Market Access, Policy and Government Affairs
Dr. Willie R. Earley M.D. Senior Vice President and Head of Clinical Development

Latest SEC Filings

Date Type Title
Mar 19, 2024 8-K Current Report
Mar 11, 2024 144 Filing
Mar 11, 2024 144 Filing
Mar 11, 2024 144 Filing
Mar 11, 2024 144 Filing
Mar 11, 2024 144 Filing
Mar 7, 2024 144 Filing
Mar 7, 2024 144 Filing
Mar 7, 2024 144 Filing
Mar 7, 2024 144 Filing